Tessera Defense and Homeland Security Inc. (HLSQ) is a NYSE American-listed physical security technology company that operates a unified platform connecting cameras, sensors, detection technologies, artificial intelligence and other security infrastructure. News related to Tessera often focuses on how the company develops and deploys integrated security solutions for homeland security, critical infrastructure, energy, digital infrastructure and enterprise environments.
Coverage of Tessera can include announcements about enhancements to its unified security platform, updates on deployments that connect detection, intelligence and response across complex sites, and developments involving its subsidiaries. Zorronet, which provides AI-powered security intelligence and autonomous command-and-control capabilities, and DFSL, which develops LADAR-based counter-UAS and perimeter security systems, may feature in reports about advanced sensing, real-time intelligence and autonomous response applications.
Another important theme in Tessera-related news is its corporate evolution. On September 11, 2026, the company changed its legal name from BiomX Inc. to Tessera Defense and Homeland Security Inc. and began trading under the HLSQ ticker, replacing PHGE. Articles and releases may reference this transition and explain that older items under the BiomX name or PHGE symbol document the issuer’s former biotechnology business rather than its current security focus.
Investors, analysts and security professionals following Tessera’s news can expect information about platform capabilities, customer segments such as critical infrastructure and homeland security organizations, and the company’s role in addressing evolving physical threats, including those involving unmanned and autonomous systems. Historical news under the BiomX identity remains part of the record but should be interpreted in light of the company’s subsequent shift to physical security technology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
BiomX (PHGE) announced positive results from Part 1 of its Phase 1b/2a trial for BX004 targeting lung infections in cystic fibrosis (CF) patients. The treatment showed a significant bacterial load reduction of over 90% compared to placebo and no safety concerns. Enrollment for Part 2 is ongoing, with results expected in Q3 2023. Financially, BiomX reported a cash balance of $34.3 million as of Dec 31, 2022, down from $63.1 million the previous year. The company estimates its cash runway extends through mid-2024, supported by a $7.5 million private placement and a $5 million award from the Cystic Fibrosis Foundation.
BiomX Inc. (NYSE American: PHGE) has announced a conference call and live audio webcast on March 29, 2023, at 8:00 a.m. ET to discuss its fourth quarter and full year 2022 financial results along with business updates. The event will provide insights into the company's progress in developing natural and engineered phage therapies targeting pathogenic bacteria. Interested participants can join by dialing 1-877-407-0724 (U.S.) or 1-201-389-0898 (International), with the live and archived webcast available on BiomX's website.
BiomX (NYSE American: PHGE) announced a securities purchase agreement to issue and sell 30,608,163 shares at $0.245 per share, raising approximately $7.5 million through a private investment in public equity (PIPE) financing. The financing will close in two parts: $1.5 million expected soon, and the remainder pending stockholder approval in Q2 2023. Proceeds will fund clinical development of BX004 for lung infections in cystic fibrosis patients and other programs. The shares are unregistered under the Securities Act and may not be sold in the U.S. without proper registration.
BiomX has reported positive results from Part 1 of its Phase 1b/2a trial for BX004, a phage therapy targeting chronic pulmonary infections in cystic fibrosis patients caused by Pseudomonas aeruginosa. The therapy was found to be safe and well-tolerated across all patients, with preliminary efficacy signals noted, including a significant reduction in bacterial burden of 1.42 log10 CFU/g compared to placebo. Patient dosing for Part 2 has commenced, with results expected in Q3 2023. This trial marks a significant advancement as the first double-blind placebo-controlled study showcasing the effectiveness of a phage-based treatment for this condition.
BiomX Inc. (NYSE American: PHGE) announced that CEO Jonathan Solomon will present at the H.C. Wainwright 1st Annual Investor Conference on Bacteriophage on November 30, 2022. The virtual presentation is scheduled for 10:30 AM EST.
BiomX is innovating in the microbiome sector with novel phage therapies targeting specific pathogenic bacteria. The presentation will be available via the Company’s website.